| Page 34 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Author(s): 
Komrokji RS, Aguirre LE, Al Ali NH, Chan O, Xie Z, Kuykendall A, Sweet K, Lancet JE, Padron E, Sallman DA
Primary Author: 
Komrokji RS
Journal Title: 
Blood Advances
Original Publication Date: 
Jul 2023
Bone Marrow Disease(s): 

Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review

Author(s): 
Mo A, Poynton M, Wood E, Shortt J, Brunskill SJ, Doree C, Sandercock J, Saadah N, Luk E, Stanworth SJ, McQuilten Z
Primary Author: 
Mo A
Journal Title: 
Blood Reviews
Original Publication Date: 
Jul 2023

Anemia is common in

Bone Marrow Disease(s): 

Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review

Author(s): 
Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR, Thakur RK, Tella SH, Patel R, Kakumani VK, Pulakurthi YS, Aluri S, Aggarwal RK, Ramachandra N, Zhao R, Sahu S, Shastri A, Verma A
Primary Author: 
Vegivinti CTR
Journal Title: 
Experimental Hematology & Oncology
Original Publication Date: 
Jul 2023

Dysregulation of the innate immune system and inflammatory-related pathways has been implicated in hematopoietic defects in the

Bone Marrow Disease(s): 

Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress

Author(s): 
Venugopal S, Shallis RM, Zeidan AM
Primary Author: 
Venugopal S
Journal Title: 
Expert Review of Anticancer Therapies
Original Publication Date: 
Jul 2023

Introduction: Patients with myeloid neoplasms such as

Bone Marrow Disease(s): 

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Author(s): 
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T
Primary Author: 
Platzbecker U
Journal Title: 
Lancet
Original Publication Date: 
Jul 2023

Background: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk

Bone Marrow Disease(s): 

Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia

Author(s): 
Zhao J, Ma L, Zheng M, Su L, Guo X
Primary Author: 
Zhao J
Journal Title: 
Annals of Hematology
Original Publication Date: 
Jul 2023

This meta-analysis was to evaluate the outcome of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) for

Bone Marrow Disease(s):